Results 1 to 10 of about 11,948 (164)

Baricitinib ameliorates skin fibrosis via direct fibroblast suppression and endothelial exosome-mediated paracrine signaling [PDF]

Arthritis Research & Therapy
Background Novel therapies are urgently needed for diffuse cutaneous systemic sclerosis (dcSSc). Aberrant JAK/STAT signaling drives fibrosis, but JAK inhibitors’ effects on vascular pathology and potential synergy with endothelial-derived exosomes remain
Zhanying Hou, Xiufeng Zhao, Fang Liu, Shi Xu   +3 more
doaj   +2 more sources

Baricitinib as Treatment Option for Corona Virus Disease-19: a Literature Review

Jurnal Kedokteran Diponegoro, 2022
Background : Treatment of COVID-19 using IL-6 inhibitors, including Sarilumab or Tocilizumab, significantly decreased mortality risk. Though, Remdesivir therapy gave benefits, morbidity and mortality remained high.
Thomas Handoyo, Nur Farhanah, Gianina Dinda Pamungkas   +2 more
doaj   +1 more source

Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial

Arthritis Research & Therapy, 2022
Background Patients with systemic lupus erythematosus (SLE) have substantial unmet medical need. Baricitinib is a Janus kinase (JAK)1 and 2 inhibitor that was shown to have therapeutic benefit in patients with SLE in a phase II clinical trial.
Thomas Dörner, Ronald F. van Vollenhoven, Andrea Doria, Bochao Jia, Jorge A. Ross Terres, Maria E. Silk, Stephanie de Bono, Peter Fischer, Daniel J. Wallace   +8 more
doaj   +1 more source

Baricitinib for atopic dermatitis patients who responded inadequately to dupilumab treatment: First daily practice results

JEADV Clinical Practice, 2022
Background Baricitinib is the first JAK inhibitor registered for the treatment of moderate‐to‐severe atopic dermatitis (AD). Efficacy and safety were shown in clinical trials, but daily practice data is sparse.
Linde deWijs, Corine Schreurs, Anne Schlösser, Tamar Nijsten, Dirk Jan Hijnen   +4 more
doaj   +1 more source

Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases

Rheumatology and Therapy, 2022
Introduction The aim of this work is to evaluate baricitinib safety with respect to venous thromboembolism (VTE), major adverse cardiovascular events (MACE), and serious infection relative to tumor necrosis factor inhibitors (TNFi) in patients with ...
Claudia A. Salinas, Anthony Louder, Jennifer Polinski, Tancy C. Zhang, Hannah Bower, Syd Phillips, Yufei Song, Emaan Rashidi, Rafia Bosan, Hsiu-Ching Chang, Nicole Foster, Bernice Gershenson, Hisashi Yamanaka, Mitsumasa Kishimoto, Yoshiya Tanaka, Peter Fischer, Baojin Zhu, Douglas Faries, Xiaodan Mai, Brett T. Doherty, Angela Grelaud, Nicolas H. Thurin, Johan Askling, Walter Deberdt, the B023 Study Consortium   +24 more
doaj   +1 more source

Real-Life Advantages and Limits of Baricitinib for the Late Treatment of Adults Hospitalized with COVID-19

BioMed, 2023
Baricitinib, a reversible Janus-associated kinase-inhibitor, is approved for treating COVID-19, combined with Dexamethasone and, eventually, with Remdesivir (RDV).
Mariacristina Poliseno, Donato Lacedonia, Mariangela Niglio, Federica De Gregorio, Graziano Antonio Minafra, Terence Campanino, Giulio Giganti, Giulia Scioscia, Teresa Antonia Santantonio, Maria Pia Foschino Barbaro, Sergio Lo Caputo   +10 more
doaj   +1 more source

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis

RMD Open, 2023
Objectives To assess the safety of the oral Janus kinase inhibitor baricitinib in adult patients with systemic lupus erythematosus (SLE) receiving stable background therapy.
Josef S Smolen, Yoshiya Tanaka, Michelle Petri, Inmaculada de la Torre, Thomas Dörner, Gabriella Meszaros, Hong Zhang, Maher Issa, Eric Morand, Christina Dickson, Maria Silk   +10 more
doaj   +1 more source

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review

Arthritis Research & Therapy, 2021
Baricitinib is an oral selective inhibitor of Janus kinase (JAK)1 and JAK2 that has proved effective and well tolerated in the treatment of rheumatoid arthritis (RA) in an extensive programme of clinical studies of patients with moderate-to-severe ...
Paul Emery, Patrick Durez, Axel J. Hueber, Inmaculada de la Torre, Esbjörn Larsson, Thorsten Holzkämper, Yoshiya Tanaka   +6 more
doaj   +1 more source

EFFICACY OF BARICITINIB IN PATIENTS TREATED WITH CORTICOSTEROIDS FOR SEVERE COVID-19 PNEUMONIA: A RETROSPECTIVE OBSERVATIONAL COHORT STUDY

International Journal of Infectious Diseases, 2023
Intro: Current evidence is still lacking in use of baricitinib among COVID-19 patients that require low flow oxygen and have systemic inflammation. Therefore, we are keen to evaluate the efficacy of baricitinib therapy among this group of patients, in ...
K.H. Tay, L.H. Benedict Sim, S.K. Chidambaram   +2 more
doaj   +1 more source

Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis

RMD Open, 2019
Objectives To evaluate radiographic progression of structural joint damage over 2 years in patients with rheumatoid arthritis from baricitinib clinical trials who were disease-modifying antirheumatic drug (DMARD)–naïve or had an inadequate response to ...
Désirée van der Heijde, Yoshiya Tanaka, Paul Emery, Li Xie, Michael Schiff, Gabriella Meszaros, Taeko Ishii, Marta Casillas, Robert A Ortmann   +8 more
doaj   +1 more source